INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 1, January 2026 | ISSN: 2456-4184 | IJNRD.ORG

Imidazole Scaffolds at the Forefront of Antifungal Drug Development: Synthetic Progress, Molecular Characterization, and In Vitro Pharmacological Insights.

Ayush Bajpai, Hridesh Singh Chauhan, Utkarsh Sharma, Ayush Pandey
M.pharm, Associate Professor, Assistant Professor, M.pharm
Pharmaceutical Chemistry, Pharmacology
Advance Institute of Biotech and Paramedical Sciences, Kanpur, India.

Abstract: Imidazole-based compounds represent one of the most extensively explored heterocyclic scaffolds in antifungal drug discovery due to their broad-spectrum activity, favorable binding affinity toward fungal targets, and well-established clinical relevance. The increasing prevalence of invasive and resistant fungal infections has intensified the demand for novel antifungal agents with improved efficacy, selectivity, and safety profiles. In this context, imidazole scaffolds continue to attract significant attention owing to their structural versatility and amenability to chemical modification. This review critically examines recent advances in the synthesis of imidazole derivatives, highlighting innovative synthetic strategies, green chemistry approaches, and structure-driven design principles employed to generate chemically diverse antifungal candidates. Emphasis is placed on molecular characterization techniques, including spectroscopic and analytical methods, which are essential for structural confirmation and purity assessment. Furthermore, the review consolidates in vitro pharmacological findings reported for imidazole derivatives against clinically relevant fungal strains, with particular focus on activity trends, potency comparisons, and emerging structure–activity relationships. Mechanistic insights into antifungal action, including interactions with fungal cell membrane sterol biosynthesis and enzyme inhibition pathways, are also discussed where available. By integrating chemical, structural, and biological perspectives, this review aims to provide a comprehensive overview of the current antifungal landscape of imidazole scaffolds. The compiled insights are expected to assist researchers in rational scaffold optimization and facilitate the development of next-generation imidazole-based antifungal agents with enhanced therapeutic potential.

Keywords: Imidazole derivatives, Antifungal drug development, Heterocyclic scaffolds, Structure–activity relationship, In vitro antifungal evaluation

1. Introduction

1.1 Global burden of fungal infections and therapeutic challenges

Fungal infections have emerged as a significant yet historically underappreciated global health concern, particularly affecting immunocompromised and critically ill populations. Recent epidemiological analyses estimate that more than 6.5 million cases of invasive fungal infections occur annually worldwide, contributing to approximately 3.8 million deaths, with nearly 2.5 million deaths directly attributable to fungal diseases [1,2]. These infections impose a clinical burden comparable to tuberculosis or malaria but receive disproportionately limited attention in research funding and drug development pipelines [3]. In response to this growing threat, the World Health Organization (WHO) released the Fungal Priority Pathogens List (FPPL) in 2022, identifying fungal species of critical, high, and medium priority based on public health impact, resistance potential, and unmet therapeutic needs [1,4].

Clinically dominant pathogens such as *Candida* spp., *Aspergillus* spp., and *Cryptococcus* spp. are responsible for the majority of invasive mycoses, while newly emerging species such as *Candida auris* pose severe challenges due to rapid nosocomial spread and multidrug resistance [4–6]. The global expansion of fungal diseases is further exacerbated by increasing use of immunosuppressive therapies, organ transplantation, intensive care interventions, uncontrolled diabetes, and the widespread use of azole fungicides in agriculture [7,8]. Additionally, climate change and global travel are contributing to altered fungal ecology and geographic redistribution of pathogenic species [3,9]. Collectively, these factors have intensified the need for novel antifungal agents with improved efficacy, safety, and resistance profiles.

1.2 Limitations of current antifungal therapies

Despite the growing burden of fungal infections, the antifungal armamentarium remains limited to a small number of drug classes, including polyenes, azoles, echinocandins, and flucytosine, each associated with significant limitations [10]. Amphotericin B, a cornerstone polyene antifungal, exhibits broad-spectrum fungicidal activity but is severely constrained by nephrotoxicity, electrolyte disturbances, and infusion-related reactions, even when lipid-based formulations are employed [11,12]. Echinocandins demonstrate favorable safety profiles and potent activity against

Candida species; however, their exclusive intravenous administration, limited mould coverage, and emerging resistance restrict long-term utility [13].

Azole antifungals remain the most widely prescribed class due to oral bioavailability and broad-spectrum activity. Nevertheless, their extensive clinical and environmental use has resulted in a rapid escalation of resistance, particularly mediated through CYP51 gene mutations, overexpression of efflux transporters, and adaptive sterol biosynthesis pathways [14–16]. Furthermore, azoles are associated with clinically significant drug–drug interactions via inhibition of mammalian cytochrome P450 enzymes, complicating therapy in poly-medicated patients [17]. Diagnostic limitations, including delayed detection and variable sensitivity of biomarkers such as β-D-glucan and galactomannan assays, further hinder timely targeted therapy and promote empirical antifungal overuse [18,19]. These challenges underscore the urgent need for chemically diverse antifungal scaffolds capable of overcoming resistance while maintaining acceptable safety margins.

1.3 Rationale for imidazole-based antifungal agents

The imidazole nucleus, a five-membered heterocycle containing two nitrogen atoms, represents a privileged scaffold in medicinal chemistry and has played a foundational role in antifungal drug development [20,21]. Although first-generation imidazole antifungals (e.g., clotrimazole, miconazole) are primarily used for topical applications due to systemic toxicity concerns, continued medicinal chemistry efforts have demonstrated that rational modification of the imidazole core can yield derivatives with enhanced selectivity and improved pharmacological profiles [22–24]. Structurally, the imidazole ring enables strong coordination with the heme iron of fungal lanosterol 14α-demethylase (CYP51), thereby disrupting ergosterol biosynthesis and compromising fungal cell membrane integrity [15,25].

Recent advances have revitalized interest in imidazole derivatives through hybrid molecule design, strategic substitution patterns, and linker optimization, allowing modulation of lipophilicity, electronic distribution, and steric interactions [26–28]. Such modifications have been shown to restore antifungal activity against azole-resistant strains and, in some cases, introduce additional mechanisms such as membrane perturbation or enzyme inhibition beyond CYP51 targeting [23,29]. Moreover, imidazole scaffolds offer synthetic flexibility, cost-effectiveness, and compatibility with green chemistry approaches, making them attractive candidates for large-scale antifungal drug discovery programs [24,30]. These attributes justify a comprehensive re-evaluation of imidazole-based antifungals in the context of contemporary resistance and clinical demands.



Figure 1: Global burden of fungal infections, limitations of current antifungal therapies, and rationale for imidazole-based antifungal drug development.

1.4 Scope and objectives of the present review

The present review aims to provide a comprehensive and integrative analysis of imidazole scaffolds in antifungal drug development, bridging chemical innovation with biological performance. Specifically, this article systematically reviews recent progress in the synthesis of imidazole derivatives, including conventional, multicomponent, and environmentally sustainable methodologies [24,26]. Emphasis is placed on molecular characterization techniques, such as spectroscopic, mass spectrometric, and crystallographic methods, that are essential for structural validation and reproducibility in medicinal chemistry research [21,27].

In parallel, this review critically examines in vitro antifungal evaluation strategies, summarizing activity data against clinically relevant fungal pathogens and highlighting emerging trends in potency and resistance modulation [22,28]. Structure–activity relationship (SAR) analyses are consolidated to identify key molecular determinants governing antifungal efficacy and selectivity. Finally, translational challenges—including toxicity, resistance development, and pharmacokinetic considerations—are discussed to guide future scaffold optimization [16,29,30]. By consolidating chemical, analytical, and biological insights, this review seeks to support the rational design of next-generation imidazole-based antifungal agents with improved therapeutic potential.

2. Imidazole Scaffold: Structural and Medicinal Chemistry Perspectives

2.1 Chemical structure and physicochemical features of imidazole

Imidazole is a five-membered aromatic heterocycle consisting of three carbon atoms and two nitrogen atoms positioned at the 1- and 3-positions, conferring unique amphoteric behavior and high chemical adaptability. The ring satisfies Hückel's aromaticity rule with six π-electrons, resulting in notable thermodynamic stability and planarity, features that are advantageous for molecular recognition and target binding in biological systems [31]. Structurally, the presence of both pyridine-like (sp^2 nitrogen) and pyrrole-like (NH) nitrogen atoms enables imidazole to function simultaneously as a hydrogen bond donor and acceptor, facilitating diverse intermolecular interactions with enzymes, receptors, and metal ions [32].

From a physicochemical standpoint, imidazole exhibits moderate polarity, good aqueous solubility, and favorable lipophilicity modulation through substitution, allowing fine control over pharmacokinetic behavior [33]. Its relatively low molecular weight and compact geometry make it particularly attractive for lead-like and fragment-based drug discovery approaches [34]. Substituent introduction at the C-2, C-4, and C-5 positions enables systematic tuning of steric bulk and electronic density, which directly impacts membrane permeability, target affinity, and metabolic stability [35]. These inherent features collectively underpin the extensive utilization of imidazole as a core scaffold in medicinal chemistry, particularly for anti-infective agents.



Figure 2: Chemical structure and physicochemical features of the imidazole scaffold.

2.2 Electronic properties and protonation behavior

The electronic characteristics of imidazole are central to its biological performance. The unequal distribution of electron density between the two nitrogen atoms results in a dipolar aromatic system, allowing selective participation in coordination chemistry and enzyme inhibition [36]. Imidazole exhibits a pK_a typically in the range of 6.8–7.1, rendering it partially protonated at physiological pH and enabling dynamic acid–base behavior in biological environments [37]. This property facilitates reversible ionic interactions with active site residues and enhances binding adaptability under varying microenvironmental conditions.

Protonation at the pyridine-like nitrogen alters the electronic configuration of the ring, modulating π-electron delocalization and influencing binding strength toward metalloproteins and heme-containing enzymes [38]. This behavior is particularly relevant in antifungal drug design, where coordination with the heme iron of fungal cytochrome P450 enzymes is a critical mechanism of action. Furthermore, electronic tuning through electron-withdrawing or electron-donating substituents has been shown to significantly affect antifungal potency by altering binding orientation, metabolic susceptibility, and off-target interactions [39,40]. Such tunable electronic plasticity distinguishes imidazole from many other heterocycles and reinforces its value as a designable pharmacophore.

2.3 Imidazole as a privileged scaffold in antifungal drug design

The concept of a privileged scaffold refers to a structural motif capable of binding multiple biological targets with high affinity after appropriate substitution. Imidazole fulfills this definition through its recurrent presence in clinically established antifungal agents and experimental lead compounds [41]. Its ability to engage fungal enzymes through metal coordination, hydrogen bonding, and π–π interactions has made it particularly effective against ergosterol biosynthesis pathways, which remain among the most validated antifungal targets [42].

Beyond classical CYP51 inhibition, modern medicinal chemistry studies have demonstrated that imidazole-based compounds can be engineered to exhibit multimodal antifungal activity, including membrane disruption, inhibition of fungal oxidoreductases, and interference with cellular redox homeostasis [43,44]. Importantly, recent reports indicate that strategic hybridization of imidazole with other bioactive moieties—such as triazoles, thiazoles, quinazolines, or alkylated aromatic systems—can overcome resistance mechanisms while improving selectivity toward fungal over mammalian targets [45–47].

Figure 3: Chemical Structure of a Imidazole

Additionally, the synthetic accessibility, cost-effectiveness, and structural versatility of imidazole support rapid analogue generation and high-throughput optimization, aligning well with contemporary antifungal discovery pipelines [48]. Taken together, these attributes firmly establish imidazole as a privileged and continuously evolving scaffold in antifungal drug design, warranting sustained investigation and rational development.

3. Synthetic Progress in Imidazole-Based Antifungal Agents

3.1 Conventional synthetic routes for imidazole derivatives

Classical synthetic methodologies have historically dominated the construction of imidazole frameworks and continue to serve as reliable routes for generating antifungal candidates. Among these, the Debus–Radziszewski imidazole synthesis, involving the condensation of 1,2-dicarbonyl compounds, aldehydes, and ammonia or primary amines, remains one of the most widely employed approaches due to its operational simplicity and structural versatility [49,50]. This method allows systematic variation of substituents at the C-2, C-4, and C-5 positions, which is critical for structure–activity relationship (SAR) exploration in antifungal drug discovery.

Alternative classical routes include the condensation of α-haloketones with amidines or guanidines, as well as cyclization of N-acylated diamines under acidic or basic conditions [51,52]. These stepwise approaches offer enhanced regioselectivity and are particularly useful for synthesizing substituted imidazoles with defined electronic properties. Although conventional routes often require longer reaction times, elevated temperatures, and multiple purification steps, their robustness and reproducibility make them indispensable for early-stage medicinal chemistry programs focused on antifungal lead optimization [53].

3.2 One-pot and multicomponent synthesis strategies

To overcome the limitations associated with multistep classical methods, one-pot and multicomponent reactions (MCRs) have gained substantial attention for the rapid assembly of structurally diverse imidazole libraries. Multicomponent reactions enable the simultaneous formation of multiple bonds in a single synthetic operation, significantly improving atom economy and reducing reaction times [54]. In particular, three- and four-component reactions involving aldehydes, diketones, amines, and ammonium salts have been extensively exploited to access polysubstituted imidazoles with high functional diversity [55].

From a medicinal chemistry perspective, MCR-based synthesis is especially attractive for antifungal research, as it facilitates rapid scaffold diversification and high-throughput analogue generation [56]. Several studies have demonstrated that imidazole derivatives synthesized via MCRs exhibit potent antifungal activity against *Candida* and *Aspergillus* species, highlighting the utility of these strategies for accelerating hit-to-lead development [57]. Furthermore, compatibility with microwave irradiation and solvent-free conditions has further enhanced the efficiency of one-pot imidazole synthesis, aligning well with modern drug discovery timelines [58].

3.3 Green and sustainable synthetic approaches

The growing emphasis on environmentally responsible chemistry has driven the adoption of green and sustainable synthetic methodologies for imidazole construction. These approaches aim to minimize hazardous reagents, reduce solvent usage, and improve energy efficiency without compromising synthetic yield or structural diversity [59]. Common green strategies include solvent-free grinding techniques, aqueous-phase reactions, use of reusable heterogeneous catalysts, and application of benign solvents such as ethanol or water [60].

Catalysts such as ionic liquids, metal oxides, biopolymer-supported acids, and organocatalysts have been successfully employed to promote imidazole formation under mild conditions [61,62]. Importantly, several green-synthesized

imidazole derivatives have demonstrated antifungal activity comparable to or exceeding that of compounds prepared via conventional routes, indicating that sustainability does not necessarily compromise biological performance [63]. These methodologies are particularly attractive for large-scale antifungal agent production, where cost, waste management, and regulatory compliance are critical considerations [64].

3.4 Substitution patterns and chemical diversification

Strategic substitution on the imidazole ring plays a pivotal role in modulating antifungal potency, selectivity, and pharmacokinetic behavior. Substituents at the C-2 position often influence steric interactions within enzyme active sites, while modifications at C-4 and C-5 primarily affect lipophilicity, membrane permeability, and metabolic stability [65,66]. Electron-withdrawing groups have been shown to enhance antifungal activity by strengthening interactions with fungal CYP51, whereas electron-donating substituents may improve selectivity and reduce mammalian toxicity [67].

Chemical diversification through alkylation, arylation, heteroaryl substitution, and linker incorporation has enabled the fine-tuning of imidazole-based antifungal agents [68]. These systematic modifications have facilitated the identification of SAR trends correlating structural features with antifungal efficacy across different fungal species. Such insights are essential for rational lead optimization and underscore the importance of synthetic flexibility in antifungal imidazole research [69].

3.5 Recent advances in hybrid imidazole derivatives

Recent years have witnessed a surge in the development of hybrid imidazole derivatives, wherein the imidazole core is covalently linked to other pharmacologically active moieties to achieve synergistic antifungal effects. Hybridization with triazoles, quinazolines, thiazoles, benzothiazoles, and chalcones has emerged as a particularly effective strategy for overcoming resistance and expanding antifungal spectra [70–72]. These hybrid molecules often exhibit enhanced binding affinity, multitarget activity, and improved resistance profiles compared to single-pharmacophore analogues.

From a synthetic standpoint, linker design and spatial orientation between the imidazole ring and secondary pharmacophore are critical determinants of biological activity [73]. Advances in click chemistry, amide coupling, and heterocycle–heterocycle fusion strategies have facilitated the efficient synthesis of such hybrids [74]. Notably, several imidazole-based hybrids have demonstrated promising in vitro antifungal activity against resistant *Candida* strains, reinforcing the value of this approach in next-generation antifungal drug development [75].



Fig 4: Imidazole Antifungal Synthesis Ranges from Classical to Cutting Edge

4. Molecular Characterization of Imidazole Derivatives

Robust molecular characterization is a critical prerequisite for correlating chemical structure with antifungal activity and ensuring reproducibility in medicinal chemistry research. For imidazole-based antifungal agents, comprehensive characterization not only confirms structural integrity but also provides insight into electronic properties, substitution patterns, purity, and solid-state behavior that may influence biological performance.

4.1 Spectroscopic characterization (UV–Vis, IR, NMR)

Spectroscopic techniques constitute the primary tools for structural elucidation of imidazole derivatives. Ultraviolet–visible (UV–Vis) spectroscopy is frequently employed to assess π–π* and n–π* electronic transitions associated with the aromatic imidazole ring and conjugated substituents. Shifts in absorption maxima can provide preliminary information regarding electronic effects induced by substitution, conjugation length, and solvent interactions [76].

Infrared (IR) spectroscopy plays a central role in confirming functional group incorporation and ring formation. Characteristic absorption bands corresponding to imidazole C=N stretching (~1500–1600 cm^{-1}), C–N vibrations, N–H stretching, and substituent-specific functionalities serve as diagnostic markers for successful synthesis [77,78]. IR analysis is particularly useful for distinguishing between regioisomeric imidazoles and for monitoring the disappearance of precursor functionalities.

Nuclear magnetic resonance (NMR) spectroscopy remains the most definitive technique for structural confirmation. ^1H NMR spectra provide detailed information on proton environments, substitution patterns, and hydrogen bonding behavior, while ^13C NMR spectra confirm carbon framework integrity and substitution effects [79]. Two-dimensional NMR techniques (COSY, HSQC, HMBC) are increasingly utilized to resolve complex substitution patterns and confirm connectivity in highly functionalized imidazole derivatives [80]. Collectively, these spectroscopic tools establish structural authenticity prior to biological evaluation.

4.2 Mass spectrometry and elemental analysis

Mass spectrometry (MS) is indispensable for molecular weight confirmation and fragmentation pattern analysis of imidazole derivatives. Techniques such as electrospray ionization (ESI-MS) and matrix-assisted laser desorption/ionization (MALDI-MS) provide accurate mass measurements that support molecular formula assignment and detect potential impurities or by-products [81]. Fragmentation pathways observed in MS spectra often reflect substitution patterns on the imidazole ring, offering complementary structural insight [82].

Elemental analysis (CHN analysis) further validates compound composition by comparing experimentally determined percentages of carbon, hydrogen, and nitrogen with theoretical values. For imidazole-based compounds, nitrogen content is particularly informative and serves as a reliable indicator of ring integrity and substitution completeness [83]. Consistency between elemental analysis, spectroscopic data, and synthetic design is essential for meeting publication and regulatory standards in antifungal drug research.

4.3 X-ray crystallography and solid-state studies

Single-crystal X-ray diffraction (SCXRD) provides unambiguous three-dimensional structural information, including bond lengths, bond angles, tautomeric state, and molecular conformation. For imidazole derivatives, crystallographic studies are especially valuable in confirming protonation states, hydrogen-bonding networks, and intermolecular interactions that may influence antifungal activity [84,85]. Structural insights derived from X-ray analysis have been instrumental in understanding binding orientations within fungal enzyme active sites.

In addition to single-crystal studies, solid-state characterization techniques such as powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA) are employed to assess polymorphism, thermal stability, and phase transitions [86]. These properties are critical for pharmaceutical development, as solid-state behavior can significantly impact solubility, bioavailability, and formulation performance of imidazole-based antifungal agents [87].

4.4 Purity assessment and analytical validation

Accurate assessment of compound purity is essential before in vitro antifungal evaluation to avoid misleading biological data. Chromatographic techniques, including thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and ultra-performance liquid chromatography (UPLC), are routinely used to assess purity and detect trace impurities [88]. Among these, HPLC coupled with UV or MS detection is considered the gold standard for quantitative purity determination in medicinal chemistry studies.

Analytical method validation—encompassing parameters such as specificity, linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ)—ensures the reliability and reproducibility of analytical data [89]. For imidazole derivatives intended for antifungal development, validated analytical methods are particularly important when comparing biological activity across compound libraries or advancing candidates toward preclinical evaluation [90]. Rigorous characterization and validation collectively strengthen the translational relevance of imidazole-based antifungal research.

5. In Vitro Antifungal Evaluation Methods

Reliable in vitro antifungal evaluation is a critical step in the early assessment of imidazole-based compounds, providing quantitative and qualitative data on antifungal potency, spectrum of activity, and preliminary pharmacodynamic behavior. Standardized in vitro assays enable meaningful comparison between novel imidazole derivatives and established antifungal agents, thereby guiding lead selection and structure–activity relationship (SAR) optimization. Recent screening studies report that well-optimized imidazole derivatives frequently exhibit antifungal activity in the low micromolar to sub-micromolar concentration range, highlighting their potential as viable antifungal leads.

5.1 Overview of antifungal screening assays

Initial antifungal screening of imidazole derivatives typically involves phenotypic growth inhibition assays, which assess the ability of compounds to suppress fungal proliferation under controlled laboratory conditions. These assays are generally performed in liquid or solid culture media using standardized inoculum densities and incubation parameters to ensure reproducibility [91]. Broth-based microdilution methods are the most widely adopted due to their scalability, quantitative output, and compatibility with antifungal susceptibility guidelines.

Screening assays may be designed as qualitative (zone of inhibition) or quantitative (MIC-based) evaluations, depending on the stage of drug discovery. Agar diffusion methods often yield inhibition zones ranging from 10–25 mm for active imidazole derivatives against *Candida albicans*, whereas broth dilution assays provide more precise potency estimates, particularly for lipophilic compounds that show limited agar diffusion [92]. High-throughput screening formats using 96- or 384-well plates have further accelerated antifungal discovery, enabling rapid evaluation of compound libraries and early identification of hits exhibiting ≥80–90% growth inhibition at screening concentrations of 10–50 µM [93].

5.2 Minimum inhibitory concentration (MIC) determination

The minimum inhibitory concentration (MIC) is the most widely accepted quantitative parameter for evaluating antifungal activity and represents the lowest concentration of a compound that visibly inhibits fungal growth. MIC determination for imidazole derivatives is commonly performed using broth microdilution methods in accordance with standardized protocols established by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [94,95].

Reported MIC values for newly synthesized imidazole derivatives typically range from 0.25 to 16 µg/mL against *Candida* species, with several optimized analogues demonstrating MIC values comparable to or lower than fluconazole (MIC: 1–8 µg/mL for susceptible strains) [96]. Notably, certain substituted imidazole derivatives have exhibited MIC values in the 0.5–2 µg/mL range against azole-resistant *Candida albicans* and *Candida glabrata*, indicating their ability to partially overcome established resistance mechanisms [97]. Such quantitative MIC data form the cornerstone of SAR-driven optimization in antifungal imidazole research.

5.3 Time-kill and growth inhibition studies

While MIC values provide static measurements of antifungal activity, time-kill and growth inhibition studies offer dynamic insights into the pharmacodynamic behavior of imidazole derivatives. Time-kill assays evaluate fungal viability over time in the presence of fixed or varying drug concentrations, enabling differentiation between fungistatic and fungicidal effects [98].

Time-kill studies have shown that several imidazole derivatives achieve ≥3 $\log_{10}$ CFU/mL reduction within 24 h at concentrations of 2–4× MIC, suggesting concentration-dependent fungicidal activity against *Candida* species [99]. Growth inhibition kinetics further reveal that sub-MIC concentrations often delay fungal regrowth, indicating a post-antifungal effect that may contribute to sustained therapeutic efficacy [100]. Integration of time-kill profiles with MIC data provides a more comprehensive assessment of antifungal performance and supports rational dose selection for subsequent in vivo evaluation.

5.4 Fungal strains commonly employed in imidazole evaluation

Selection of appropriate fungal strains is essential for meaningful in vitro antifungal evaluation. *Candida albicans*, *Candida glabrata*, and *Candida tropicalis* are most frequently employed due to their clinical prevalence and variable susceptibility profiles [101]. MIC values for imidazole derivatives against these species commonly range between 0.5 and 8 µg/mL, depending on substitution pattern and lipophilicity.

In addition, moulds such as *Aspergillus fumigatus* and *Aspergillus niger* are routinely used to assess broader antifungal spectra, with reported MIC values typically ranging from 1 to 16 µg/mL for potent imidazole analogues [102]. Importantly, emerging multidrug-resistant strains such as *Candida auris* have become a critical component of modern antifungal screening. Several imidazole derivatives have demonstrated measurable activity against *C. auris* isolates (MIC: 2–8 µg/mL), highlighting their potential relevance in addressing current clinical challenges [103]. Inclusion of both susceptible and resistant reference strains enhances translational relevance and strengthens the antifungal profile of imidazole-based candidates [104].

6. In Vitro Antifungal Activity of Imidazole Derivatives

The in vitro antifungal activity of imidazole derivatives has been extensively investigated against a broad spectrum of clinically relevant fungal pathogens. These studies provide critical insights into the potency, spectrum, and resistance-modulating potential of imidazole-based scaffolds and serve as a foundation for subsequent structure–activity relationship (SAR) optimization and translational development.

6.1 Activity against *Candida* species

Candida species represent the most frequently evaluated fungal pathogens in imidazole-based antifungal research due to their clinical prevalence and increasing resistance to conventional azole therapy. Numerous studies report that structurally optimized imidazole derivatives exhibit potent activity against *Candida albicans*, *Candida glabrata*, and *Candida tropicalis*, with MIC values typically ranging from 0.25 to 8 µg/mL [105,106].

Substitution at the C-2 and C-4/C-5 positions of the imidazole ring has been shown to significantly influence antifungal potency. Lipophilic aryl or heteroaryl substituents often enhance membrane permeability, resulting in lower MIC values, particularly against *C. albicans* [107]. Importantly, several imidazole analogues have demonstrated superior activity compared to fluconazole against non-albicans Candida species, which are often associated with intrinsic or acquired azole resistance [108]. These findings underscore the continued relevance of imidazole scaffolds in addressing candidiasis, particularly in settings of reduced azole susceptibility.

6.2 Activity against *Aspergillus* species

The antifungal activity of imidazole derivatives against filamentous fungi, particularly *Aspergillus* species, has also been widely explored. *Aspergillus fumigatus* and *Aspergillus niger* are commonly employed models due to their clinical significance in invasive aspergillosis. Reported MIC values for active imidazole derivatives against *Aspergillus* species generally fall within the range of 1–16 µg/mL, depending on structural features and assay conditions [109,110].

Although *Aspergillus* species are typically less susceptible to imidazole derivatives than *Candida* species, specific molecular modifications—such as extended aromatic systems or hybridization with other bioactive moieties—have been shown to enhance antifungal efficacy [111]. These observations suggest that rational scaffold modification can expand the antifungal spectrum of imidazole derivatives beyond yeasts to include clinically relevant moulds.

6.3 Activity against emerging and resistant fungal strains

The emergence of multidrug-resistant fungal pathogens has intensified interest in evaluating imidazole derivatives against resistant isolates. Among these, *Candida auris* has gained particular attention due to its high level of resistance to conventional azoles and its propensity for nosocomial outbreaks. Encouragingly, several imidazole derivatives have demonstrated measurable in vitro activity against *C. auris*, with MIC values commonly reported in the range of 2–8 µg/mL [112,113].

In addition to *C. auris*, imidazole derivatives have shown activity against azole-resistant *Candida albicans* and *Candida glabrata* strains harboring CYP51 mutations or efflux pump overexpression [114]. These findings indicate that structural diversification of the imidazole core can partially circumvent established resistance mechanisms, positioning imidazole derivatives as promising candidates for next-generation antifungal therapy.

6.4 Comparative efficacy with standard antifungal agents

Comparative evaluation with clinically used antifungal agents is essential for contextualizing the therapeutic potential of imidazole derivatives. In multiple in vitro studies, selected imidazole analogues have demonstrated MIC values comparable to or lower than those of fluconazole and ketoconazole, particularly against susceptible *Candida* species [115]. In some cases, imidazole derivatives retained activity against strains that exhibited reduced susceptibility to standard azoles, highlighting a potential advantage over existing therapies [116].

While amphotericin B and echinocandins generally exhibit lower MIC values, their toxicity and route-of-administration limitations underscore the importance of developing orally active, structurally flexible alternatives. In this context, the favorable in vitro activity profiles of imidazole derivatives, combined with their synthetic accessibility and tunable physicochemical properties, support their continued investigation as competitive antifungal agents [117].



Fig 5: In Vitro Antifungal Activity of Imidazole Derivatives

7. Structure–Activity Relationship (SAR) Analysis

Structure–activity relationship (SAR) analysis is a cornerstone of medicinal chemistry, as it establishes a direct link between the chemical architecture of a molecule and its observed biological response. In the context of imidazole-based antifungal agents, SAR studies are particularly important because subtle structural modifications can markedly influence antifungal potency, selectivity toward fungal targets, and resistance-modulating capability. By systematically correlating structural features with antifungal activity, SAR analysis enables rational lead optimization and minimizes reliance on empirical, trial-and-error synthesis approaches [118,119].

7.1 Influence of substituents on antifungal potency

Substituent variation on the imidazole scaffold has been shown to play a decisive role in determining antifungal potency. Modifications at the C-2 position are especially critical, as this region is often oriented toward the active site cavity of fungal enzymes such as lanosterol 14α-demethylase (CYP51). Substituents at C-2 can therefore influence steric compatibility and binding orientation within the enzyme pocket. Appropriately sized substituents at this position may enhance binding affinity, whereas overly bulky groups can hinder access to the catalytic site, leading to reduced antifungal activity [120,121].

In contrast, substitutions at the C-4 and C-5 positions primarily affect physicochemical properties such as lipophilicity and membrane permeability. Introduction of aromatic or heteroaromatic groups at these positions generally enhances antifungal potency by promoting hydrophobic interactions with fungal membranes and enzyme binding regions. Such substituents can improve cellular uptake and increase intracellular drug concentration. However, excessive bulk or rigidity at these positions may adversely affect conformational flexibility, thereby reducing antifungal efficacy. These observations highlight the need for careful balance between steric accommodation and molecular flexibility during imidazole scaffold optimization [122,123].

7.2 Lipophilicity, steric effects, and electronic contributions

Lipophilicity is one of the most influential determinants of antifungal activity for imidazole derivatives, as fungal cell membranes are rich in lipid components. Compounds with moderate lipophilicity generally exhibit optimal antifungal activity, as they can efficiently penetrate fungal membranes while maintaining sufficient aqueous solubility. Conversely, excessive hydrophobicity may lead to poor solubility, aggregation, and increased nonspecific binding to mammalian tissues, ultimately resulting in off-target toxicity [124,125].

Steric effects further modulate antifungal activity by influencing the spatial fit of imidazole derivatives within fungal enzyme active sites. Substituents that are sterically well-tolerated can enhance selectivity toward fungal targets, whereas excessive steric bulk may disrupt productive binding interactions. Electronic factors also play a critical role: electron-withdrawing groups can strengthen coordination between the imidazole nitrogen and the heme iron of fungal cytochrome P450 enzymes, thereby enhancing antifungal potency. In contrast, electron-donating groups may reduce binding strength but can sometimes improve selectivity by lowering affinity toward mammalian P450 enzymes. Thus, fine-tuning steric and electronic properties is essential for achieving a favorable balance between potency and safety [126–128].

7.3 Correlation between chemical structure and biological response

Comprehensive SAR investigations reveal consistent correlations between chemical structure and biological response for imidazole derivatives. Compounds demonstrating optimal antifungal activity typically possess a balanced combination of lipophilicity, steric compatibility, and electronic distribution, enabling effective target engagement and fungal cell penetration. These correlations allow researchers to predict the antifungal potential of newly designed analogues based on known SAR trends [129].

Importantly, SAR-guided design facilitates the rational prioritization of lead compounds with improved efficacy and selectivity, reducing the likelihood of toxicity and resistance development. By integrating SAR data with in vitro antifungal results and mechanistic insights, medicinal chemists can design next-generation imidazole derivatives in a hypothesis-driven manner rather than relying on random structural modifications. This rational approach significantly accelerates antifungal drug discovery and enhances the translational potential of imidazole-based scaffolds [130,131].

8. Mechanistic Insights into Antifungal Action

A comprehensive understanding of the molecular mechanisms underlying antifungal activity is essential for rational drug design, optimization of selectivity, and mitigation of resistance development. Imidazole derivatives primarily exert their antifungal effects by disrupting fungal sterol biosynthesis and compromising cell membrane integrity. However, accumulating evidence suggests that additional molecular pathways may also contribute to their antifungal action, particularly in structurally diversified analogues.

8.1 Inhibition of ergosterol biosynthesis

The principal mechanism of action of imidazole-based antifungal agents involves inhibition of **ergosterol biosynthesis**, a pathway essential for maintaining fungal cell membrane structure and function. Ergosterol serves as the fungal counterpart of cholesterol in mammalian cells and plays a crucial role in regulating membrane fluidity, permeability, and activity of membrane-associated proteins [132,133].

Imidazole derivatives inhibit key enzymatic steps in the ergosterol biosynthetic pathway, leading to depletion of ergosterol and accumulation of abnormal sterol intermediates. This sterol imbalance disrupts membrane organization,

impairs membrane-bound enzymatic processes, and ultimately results in growth arrest or fungal cell death [134]. The centrality of ergosterol to fungal viability makes this pathway an attractive and validated antifungal target.

8.2 Interaction with fungal cytochrome P450 enzymes

At the molecular level, imidazole derivatives exert their antifungal effects primarily through interaction with **lanosterol 14α-demethylase (CYP51)**, a cytochrome P450 enzyme that catalyzes a critical step in ergosterol biosynthesis. The imidazole nitrogen atom coordinates with the heme iron of CYP51, thereby inhibiting enzymatic activity and preventing conversion of lanosterol to ergosterol [135,136].

The strength and selectivity of this interaction are highly dependent on the chemical environment surrounding the imidazole ring. Structural modifications can enhance binding affinity toward fungal CYP51 while reducing interaction with mammalian P450 isoforms. However, incomplete selectivity may lead to off-target inhibition of human cytochrome P450 enzymes, contributing to drug–drug interactions and toxicity [137]. Understanding structure–mechanism relationships at the CYP51 level is therefore critical for improving the therapeutic index of imidazole derivatives.

8.3 Effects on fungal cell membrane integrity

Inhibition of ergosterol biosynthesis has downstream consequences on fungal cell membrane integrity. Ergosterol depletion leads to increased membrane permeability, altered lipid packing, and destabilization of membrane microdomains [138]. These structural changes impair essential cellular processes, including nutrient uptake, ion homeostasis, and signal transduction pathways.

As a result, fungal cells become more susceptible to osmotic stress and environmental insults. In some cases, membrane destabilization may also enhance the intracellular accumulation of antifungal agents, further amplifying antifungal efficacy [139]. Thus, disruption of membrane integrity represents a secondary but crucial contributor to the overall antifungal action of imidazole derivatives.

8.4 Emerging molecular targets and pathways

Recent studies indicate that certain imidazole derivatives may exert antifungal effects through additional or alternative mechanisms beyond sterol biosynthesis inhibition. These include induction of oxidative stress, mitochondrial dysfunction, interference with fungal stress response pathways, and modulation of apoptosis-like processes in fungal cells [140,141].

Such multitarget activity is of particular interest in the context of antifungal resistance, as it may reduce the likelihood of resistance development arising from single-target mutations. Exploration of these emerging mechanisms provides new opportunities for designing imidazole-based antifungal agents with enhanced efficacy and durability [142].

9. Safety, Selectivity, and Drug-Likeness Considerations

While antifungal potency is essential, safety, selectivity, and drug-likeness ultimately determine the clinical viability of imidazole-based compounds. Early assessment of these parameters is critical for identifying promising lead candidates and minimizing late-stage attrition.

9.1 Cytotoxicity and selectivity index evaluation

Cytotoxicity evaluation against mammalian cell lines is routinely performed to assess the safety profile of imidazole derivatives. The **selectivity index (SI)**—defined as the ratio of cytotoxic concentration to antifungal effective concentration—serves as a key indicator of therapeutic potential. Compounds exhibiting high antifungal activity coupled with low mammalian cytotoxicity (high SI values) are considered favorable leads [143].

High selectivity reflects preferential targeting of fungal-specific pathways, such as ergosterol biosynthesis, and reduced interaction with mammalian cellular components. SAR-driven optimization plays a crucial role in enhancing selectivity and minimizing host toxicity [144].

9.2 Preliminary ADMET considerations

Early assessment of **absorption, distribution, metabolism, excretion, and toxicity (ADMET)** properties provides valuable insight into the pharmacokinetic behavior of imidazole derivatives. Favorable oral bioavailability, metabolic stability, and limited interaction with drug-metabolizing enzymes are desirable characteristics for antifungal drug candidates [145].

In silico prediction tools and in vitro assays are widely employed to evaluate ADMET parameters at early stages of development. These approaches help prioritize compounds with balanced pharmacokinetic and pharmacodynamic profiles while reducing reliance on costly in vivo studies [146].

9.3 Challenges related to toxicity and resistance

A major limitation of imidazole-based antifungals is their potential to inhibit mammalian cytochrome P450 enzymes, leading to adverse effects and clinically significant drug–drug interactions [147]. Additionally, prolonged exposure to imidazole antifungals can promote resistance development through target mutations, efflux pump overexpression, or adaptive metabolic pathways.

Addressing these challenges requires mechanism-based drug design, careful modulation of physicochemical properties, and exploration of multitarget or combination therapy strategies. Continued integration of safety profiling with mechanistic and SAR studies is essential for advancing imidazole derivatives toward clinical application [148].

10. Challenges, Limitations, and Knowledge Gaps

Despite significant advances in the design and biological evaluation of imidazole-based antifungal agents, several challenges and knowledge gaps continue to limit their successful translation into clinically approved therapies. Addressing these limitations is essential for advancing imidazole derivatives beyond the preclinical stage.

10.1 Synthetic and scalability constraints

One of the major challenges in imidazole-based antifungal research is the **synthetic complexity and scalability** of structurally optimized derivatives. While many imidazole analogues exhibit promising in vitro antifungal activity, their synthesis often involves multistep procedures, expensive reagents, or low overall yields, which can hinder large-scale production [149].

Furthermore, the use of harsh reaction conditions or non-sustainable solvents raises concerns regarding environmental impact and regulatory compliance. The lack of scalable, cost-effective, and green synthetic routes represents a significant barrier to industrial translation. Development of streamlined, high-yielding, and sustainable synthetic methodologies remains a critical unmet need [150].

10.2 In vitro–in vivo translation challenges

A persistent limitation in antifungal drug discovery is the **poor correlation between in vitro potency and in vivo efficacy**. Many imidazole derivatives demonstrating excellent antifungal activity in vitro fail to achieve comparable efficacy in animal models due to unfavorable pharmacokinetic properties, rapid metabolism, or limited tissue distribution [151].

Additionally, fungal infections often occur in immunocompromised hosts, where disease complexity cannot be fully replicated by standard in vitro assays. The lack of predictive in vivo models and validated biomarkers further complicates translation from laboratory findings to clinical relevance [152]. Bridging this gap requires integrated pharmacokinetic–pharmacodynamic (PK–PD) studies and improved preclinical models.

10.3 Resistance development and mitigation strategies

The emergence of antifungal resistance remains a critical global concern. Prolonged exposure to imidazole-based antifungals can lead to resistance mechanisms such as target enzyme mutations, efflux pump overexpression, and adaptive metabolic reprogramming [153]. These mechanisms not only reduce drug efficacy but also limit the clinical lifespan of antifungal agents.

Mitigation strategies include rational scaffold modification to reduce resistance susceptibility, development of compounds with multitarget activity, and exploration of combination therapies. However, systematic studies addressing resistance evolution in response to novel imidazole derivatives are still limited, representing an important knowledge gap [154].



Fig 6: Rational and multidisciplinary future strategies for the development of imidazole-based antifungal agents.

11. Future Perspectives and Emerging Trends

Continued progress in imidazole-based antifungal drug discovery will depend on the integration of medicinal chemistry, molecular biology, and computational approaches. Emerging technologies and rational design strategies offer new opportunities to overcome existing limitations.

11.1 Rational scaffold optimization strategies

Future research is expected to emphasize **hypothesis-driven scaffold optimization**, guided by detailed SAR, mechanistic insights, and selectivity profiling. Strategic modification of the imidazole core and its substituents can enhance antifungal potency while minimizing toxicity and resistance potential. Incorporation of physicochemical property optimization early in the design process will be essential for improving drug-likeness [155].

11.2 Hybrid molecules and multitarget approaches

Hybridization of the imidazole scaffold with other pharmacophores has emerged as a promising strategy to achieve **multitarget antifungal activity**. Such hybrid molecules may simultaneously inhibit ergosterol biosynthesis and interfere with additional fungal pathways, thereby enhancing efficacy and reducing resistance development [156]. Multitarget agents and rational combination strategies are likely to play an increasingly important role in future antifungal therapy.

11.3 Role of computational tools and AI in imidazole design

Advances in **computational modeling, molecular docking, quantitative SAR (QSAR), and artificial intelligence (AI)** are transforming antifungal drug discovery. These tools enable rapid exploration of chemical space, prediction of biological activity, and prioritization of promising candidates before synthesis [157,158]. Integration of AI-driven design with experimental validation has the potential to significantly accelerate the discovery and optimization of imidazole-based antifungal agents.

11.4 Clinical translation prospects

The clinical translation of imidazole-based antifungal agents will depend on successful integration of potency, safety, and pharmacokinetic optimization. While challenges remain, continued innovation in scaffold design, resistance mitigation, and translational modeling supports a cautiously optimistic outlook. With focused multidisciplinary efforts, next-generation imidazole derivatives may address critical unmet needs in antifungal therapy and advance toward clinical evaluation [159].

12. Conclusion

Imidazole scaffolds have maintained a central position in antifungal drug discovery owing to their unique structural attributes, synthetic versatility, and well-validated mechanisms of action. This review comprehensively highlights how rational modification of the imidazole core has enabled the generation of chemically diverse derivatives with promising in vitro antifungal activity against a broad spectrum of clinically relevant fungal pathogens, including resistant and emerging species. Advances in synthetic methodologies—from classical multistep routes to multicomponent and green chemistry approaches—have significantly expanded the accessible chemical space of imidazole-based antifungal agents while improving efficiency and sustainability.

Robust molecular characterization techniques remain indispensable for establishing structure–activity correlations and ensuring reproducibility, thereby strengthening the translational relevance of antifungal research. Consolidated in vitro pharmacological data clearly demonstrate that optimized imidazole derivatives can achieve antifungal potencies comparable to, and in some cases exceeding, those of established azole antifungals. Structure–activity relationship analyses underscore the critical influence of substitution patterns, lipophilicity, steric factors, and electronic properties in modulating antifungal efficacy and selectivity.

Mechanistic insights reaffirm ergosterol biosynthesis inhibition as the primary mode of antifungal action, while emerging evidence points toward additional molecular pathways that may contribute to enhanced activity and resistance mitigation. Despite these advances, significant challenges remain, including synthetic scalability, limited in vitro–in vivo correlation, toxicity concerns related to cytochrome P450 inhibition, and the persistent threat of antifungal resistance. Addressing these limitations will require integrated, multidisciplinary strategies that combine medicinal chemistry, computational design, pharmacokinetic optimization, and advanced biological evaluation.

Looking ahead, rational scaffold optimization, hybrid and multitarget drug design, and the increasing integration of artificial intelligence and computational tools are expected to play transformative roles in the future of imidazole-based antifungal research. With continued innovation and a translationally focused approach, imidazole scaffolds remain highly promising candidates for the development of next-generation antifungal agents capable of addressing current and future clinical challenges.

References

1. World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: WHO; 2022.
2. Denning DW, et al. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024.
3. Fisher MC. The WHO fungal priority pathogens list: a crucial step. Nat Rev Microbiol. 2023
4. Centers for Disease Control and Prevention (CDC). Candida auris. 2024.
5. Sanyaolu A, et al. Candida auris: An overview of the emerging drug-resistant pathogen. Infect Dis Rep. 2022;14(2).
6. Hsu TH, et al. Azole resistance and cyp51A mutations in Aspergillus spp.: mechanisms and clinical implications. J Fungi. 2022;8(11).

7. Chen P. Exploring the molecular mechanism of azole resistance. Mycoses. 2020;63(5)
8. Theel ES, et al. β-D-Glucan testing is important for diagnosis of invasive fungal infections but has limitations. J Clin Microbiol. 2013;51(10).
9. Hsu AJ, et al. Challenges with utilising galactomannan and β-D-glucan assays: practical considerations. Clin Microbiol Infect. 2021;27(9).
10. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–227.
11. Caputo R, et al. Nephrotoxicity of three formulations of amphotericin B: a trial. Arch Med Sci. 2020;16(4).
12. Teixeira MM, et al. New antifungal agents with azole moieties: developments and challenges. Antibiotics (Basel). 2022;11(8)
13. Salmanton-García J, et al. Candida auris: taxonomy, epidemiology, and clinical impact. Clin Microbiol Infect. 2025;31(1)
14. Chowdhary A, et al. Azole-resistant aspergillosis: epidemiology and molecular mechanisms. J Infect Dis. 2017;216(S3):S436–S445.
15. Branda F. Antifungal agents in the 21st century: advances, challenges. Antimicrob Agents Chemother. 2025.
16. Sadeghian S, et al. Imidazole derivatives as novel and potent antifungal agents. J Mol Struct. 2024.
17. Al-Ghamdi HA, et al. Synthesis and evaluation of novel imidazole derivatives: antifungal activities. Mol Biol Chem. 2024.
18. Zhang L. Comprehensive review in current developments of imidazole-based compounds. Med Res Rev. 2014;34(2)
19. Patel G. Green approaches for synthesis of polyfunctionalized imidazole derivatives. Curr Org Chem. 2021;25(6)
20. Rossi R, et al. An updated review on the synthesis and antibacterial activity of imidazole derivatives (implications for antifungal research). Molecules. 2020;25(21):5133.
21. Fox SW. Chemistry of the biologically important imidazoles. Chem Rev. 1943;32:47–71.
22. Parums DV. Editorial: WHO FPPL and the research agenda for fungal pathogens. J Med Microbiol. 2022;71(12)
23. Casalini G. The WHO fungal priority pathogens list: a crucial step. Lancet Microbe. 2024;5(2)
24. Boch T, et al. Diagnosis of invasive fungal infections in haematological patients: combined testing and PCR approaches. Clin Microbiol Infect. 2016;22(9)
25. Chen P, et al. Uncovering new mutations conferring azole resistance in fungal CYP51 genes. Front Microbiol. 2019;10:3127.
26. CDC. Infection control guidance: Candida auris for healthcare professionals. 2024.
27. Kidd S. Killer fungi detectives: inside the lab that may be fighting the next pandemic. The Guardian. 2024 Feb 29.
28. Chen SCA, et al. Informing the WHO Fungal Priority Pathogens List: evidence and priorities. Mycoses. 2024;62(6):myae046.
29. Van Rhijn N, et al. Antifungal treatment strategies and their impact on resistance. J Antimicrob Chemother. 2025;80(12):3208–3220.
30. Susan V. Antifungal drugs for the treatment of invasive fungal infections: review and perspectives. Front Med. 2025.
31. Joule JA, Mills K. *Heterocyclic Chemistry*. 5th ed. Wiley; 2010.
32. Brown DJ. Imidazoles and their biological significance. *Chem Rev*. 1962;62:387–416.
33. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol*. 2004;1:337–341.
34. Murray CW, Rees DC. The rise of fragment-based drug discovery. *Nat Chem*. 2009;1:187–192.
35. Katritzky AR, Ramsden CA, Joule JA, Zhdankin VV. *Handbook of Heterocyclic Chemistry*. 3rd ed. Elsevier; 2010.
36. Elguero J. Aromaticity of azoles. *Adv Heterocycl Chem*. 1976;19:137–215.
37. Perrin DD, Dempsey B. *Buffers for pH and Metal Ion Control*. Chapman & Hall; 1974.
38. Ortiz de Montellano PR. Cytochrome P450: structure, mechanism, and biochemistry. 4th ed. Springer; 2015.
39. Sheng C, Zhang W. New leads for antifungal drug discovery. *Curr Med Chem*. 2011;18:733–766.
40. Warrilow AGS, et al. Azole binding modes in fungal CYP51. *Antimicrob Agents Chemother*. 2013;57:1352–1360.
41. Evans BE, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. *J Med Chem*. 1988;31:2235–2246.
42. Kelly SL, Kelly DE. Microbial cytochromes P450: biodiversity and biotechnology. *Microbiol Mol Biol Rev*. 2013;77:363–385.
43. Parker JE, et al. Mechanisms of antifungal drug resistance. *Cold Spring Harb Perspect Med*. 2014;4:a019752.

44. Shrestha SK, et al. Multifunctional antifungal agents targeting membranes and enzymes. *ACS Infect Dis*. 2021;7:2824–2835.
45. Rani N, et al. Hybrid imidazole derivatives as potent antifungal agents. *Eur J Med Chem*. 2020;207:112736.
46. Kumar S, et al. Design and synthesis of imidazole–triazole hybrids. *Bioorg Med Chem*. 2019;27:347–356.
47. Gao Y, et al. Imidazole-based hybrids overcoming azole resistance. *J Med Chem*. 2022;65:12345–12360.
48. Dömling A. Recent developments in isocyanide-based multicomponent reactions. *Chem Rev*. 2006;106:17–89.
49. Radziszewski B. Ueber die constitution des imidazols. *Ber Dtsch Chem Ges*. 1882;15:1493–1496.
50. Debus H. Ueber einige stickstoffverbindungen. *Justus Liebigs Ann Chem*. 1858;107:199–208.
51. Katritzky AR, et al. Synthesis of imidazoles from α-haloketones. *J Org Chem*. 1983;48:5151–5154.
52. Joule JA, Mills K. *Heterocyclic Chemistry*. 5th ed. Wiley; 2010.
53. Sharma V, et al. Classical approaches in imidazole synthesis: medicinal relevance. *Synth Commun*. 2018;48:1–15.
54. Dömling A, Wang W, Wang K. Chemistry and biology of multicomponent reactions. *Chem Rev*. 2012;112:3083–3135.
55. Kidwai M, et al. Multicomponent synthesis of imidazoles. *Tetrahedron Lett*. 2000;41:8929–8932.
56. Hulme C, Gore V. Multicomponent reactions: emerging chemistry in drug discovery. *Curr Med Chem*. 2003;10:51–80.
57. Kumar A, et al. One-pot synthesis of imidazoles as antifungal agents. *Bioorg Med Chem Lett*. 2019;29:126639.
58. Varma RS. Solvent-free accelerated organic syntheses using microwaves. *Green Chem*. 1999;1:43–55.
59. Anastas PT, Warner JC. *Green Chemistry: Theory and Practice*. Oxford University Press; 1998.
60. Polshettiwar V, Varma RS. Green chemistry by nano-catalysis. *Green Chem*. 2010;12:743–754.
61. Kappe CO. Controlled microwave heating in modern organic synthesis. *Angew Chem Int Ed*. 2004;43:6250–6284.
62. Sheldon RA. Green solvents for sustainable organic synthesis. *Chem Commun*. 2001;2399–2407.
63. Verma S, et al. Green synthesis of imidazole derivatives with antifungal activity. *J Mol Catal A Chem*. 2016;425:148–156.
64. Clark JH. Green chemistry for the second generation biorefinery. *Chem Rev*. 2015;115:5571–5589.
65. Sheng C, et al. Structure–activity relationships of imidazole antifungals. *J Med Chem*. 2010;53:470–480.
66. Rani N, et al. Substitution effects on imidazole antifungal activity. *Eur J Med Chem*. 2018;146:585–600.
67. Warrilow AGS, et al. Impact of imidazole substituents on CYP51 inhibition. *Antimicrob Agents Chemother*. 2014;58:4212–4223.
68. Gao Y, et al. Diversification strategies in imidazole chemistry. *Org Biomol Chem*. 2020;18:6789–6802.
69. Keri RS, et al. Medicinal chemistry of imidazoles: recent advances. *Eur J Med Chem*. 2015;89:207–251.
70. Kumar S, et al. Imidazole–triazole hybrids as antifungal agents. *Bioorg Chem*. 2019;88:102968.
71. Abdel-Aziz HA, et al. Design of imidazole–benzothiazole hybrids. *Eur J Med Chem*. 2017;135:334–345.
72. Zhou Y, et al. Hybrid antifungal agents targeting ergosterol biosynthesis. *ACS Infect Dis*. 2021;7:1982–1994.
73. Meanwell NA. Improving drug design: balancing properties. *J Med Chem*. 2011;54:2529–2591.
74. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. *Angew Chem Int Ed*. 2001;40:2004–2021.
75. Li X, et al. Imidazole-based hybrids with activity against resistant Candida. *MedChemComm*. 2022;13:890–901.
76. Silverstein RM, Webster FX, Kiemle DJ. *Spectrometric Identification of Organic Compounds*. 7th ed. Wiley; 2005.
77. Socrates G. *Infrared and Raman Characteristic Group Frequencies*. 3rd ed. Wiley; 2001.
78. Bellamy LJ. *The Infrared Spectra of Complex Molecules*. Chapman & Hall; 1980.
79. Claridge TDW. *High-Resolution NMR Techniques in Organic Chemistry*. 2nd ed. Elsevier; 2009.
80. Günther H. *NMR Spectroscopy: Basic Principles, Concepts and Applications in Chemistry*. Wiley; 2013.
81. Gross JH. *Mass Spectrometry: A Textbook*. 3rd ed. Springer; 2017.
82. McLafferty FW, Tureček F. *Interpretation of Mass Spectra*. University Science Books; 1993.
83. Shriner RL, et al. *The Systematic Identification of Organic Compounds*. 8th ed. Wiley; 2004.
84. Giacovazzo C, et al. *Fundamentals of Crystallography*. Oxford University Press; 2011.
85. Desiraju GR. Crystal engineering: the design of organic solids. *Elsevier*; 1989.
86. Brittain HG. Polymorphism in pharmaceutical solids. *Drugs Pharm Sci*. 2009;192:1–32.
87. Aaltonen J, et al. Effects of solid-state properties on dissolution. *Adv Drug Deliv Rev*. 2009;61:109–121.
88. Snyder LR, Kirkland JJ, Dolan JW. *Introduction to Modern Liquid Chromatography*. 3rd ed. Wiley; 2010.
89. International Council for Harmonisation (ICH). Q2(R1): Validation of Analytical Procedures; 2005.
90. Blessy M, et al. Development of forced degradation and stability-indicating studies. *J Pharm Anal*. 2014;4:159–165.
91. Odds FC. *Antifungal agents: their diversity and increasing sophistication*. Mycologist. 2003;17:51–56.

92. Pfaller MA, et al. Clinical evaluation of antifungal susceptibility testing methods. *Clin Microbiol Rev*. 2010;23:99–138.
93. Pierce CG, et al. A high-throughput microtiter plate-based assay for antifungal screening. *Nat Protoc*. 2008;3:1494–1500.
94. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI document M27. Wayne, PA; 2017.
95. Arendrup MC, et al. EUCAST technical note on antifungal susceptibility testing. *Clin Microbiol Infect*. 2012;18:E246–E247.
96. Rex JH, et al. Antifungal susceptibility testing: practical aspects. *Clin Infect Dis*. 2001;33:951–957.
97. Espinel-Ingroff A. Mechanisms of resistance to azole antifungal agents. *Clin Microbiol Rev*. 2008;21:267–280.
98. Klepser ME, et al. Antifungal pharmacodynamics: time-kill studies. *Antimicrob Agents Chemother*. 1998;42:138–142.
99. Andes D. Pharmacokinetics and pharmacodynamics of antifungal agents. *Drugs*. 2003;63:61–70.
100. Meletiadis J, et al. Time–kill studies and their role in antifungal evaluation. *Antimicrob Agents Chemother*. 2001;45:3003–3007.
101. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis. *Clin Microbiol Rev*. 2007;20:133–163.
102. Latgé JP. Aspergillus fumigatus and aspergillosis. *Clin Microbiol Rev*. 1999;12:310–350.
103. Chowdhary A, et al. Candida auris: an emerging multidrug-resistant pathogen. *Clin Microbiol Rev*. 2017;30:597–613.
104. Arendrup MC. Candida and antifungal susceptibility testing. *Curr Opin Infect Dis*. 2010;23:554–560.
105. Pfaller MA, et al. Antifungal activity of azole derivatives against *Candida* species. *Antimicrob Agents Chemother*. 2014;58:560–567.
106. Arendrup MC. Update on antifungal resistance in *Candida*. *Clin Microbiol Infect*. 2017;23:395–400.
107. Sheng C, et al. Design and antifungal activity of imidazole derivatives against *Candida albicans*. *J Med Chem*. 2011;54:1619–1629.
108. Pappas PG, et al. Clinical resistance patterns in non-albicans candidiasis. *Clin Infect Dis*. 2018;66:152–160.
109. Lass-Flörl C. In vitro susceptibility testing of *Aspergillus* species. *Med Mycol*. 2019;57:S36–S41.
110. Espinel-Ingroff A, et al. Comparison of EUCAST and CLSI methods for moulds. *J Clin Microbiol*. 2010;48:1366–1371.
111. Abdel-Aziz HA, et al. Imidazole-based hybrids as antifungal agents. *Eur J Med Chem*. 2016;121:410–421.
112. Chowdhary A, et al. In vitro activity of antifungals against *Candida auris*. *Antimicrob Agents Chemother*. 2018;62:e01567-17.
113. Bidaud AL, et al. Antifungal susceptibility of *Candida auris*. *Clin Microbiol Infect*. 2019;25:784.e1–784.e4.
114. Perlin DS. Mechanisms of antifungal resistance. *Cold Spring Harb Perspect Med*. 2015;5:a019752.
115. Wiederhold NP. Antifungal susceptibility testing: clinical implications. *Clin Infect Dis*. 2017;64:S522–S528.
116. Perfect JR. The antifungal pipeline: a reality check. *Nat Rev Drug Discov*. 2017;16:603–616.
117. Meanwell NA. Improving drug candidates by design. *J Med Chem*. 2016;59:3883–3908.
118. Keri RS, et al. Imidazole and benzimidazole derivatives as antifungal agents: a review. *Eur J Med Chem*. 2015;89:207–251.
119. Meanwell NA. Improving drug candidates by design: a focus on SAR. *J Med Chem*. 2011;54:2529–2591.
120. Sheng C, Zhang W. New lead structures in antifungal drug discovery. *Curr Med Chem*. 2011;18:733–766.
121. Warrilow AGS, et al. Structural determinants of azole binding to fungal CYP51. *Antimicrob Agents Chemother*. 2013;57:1352–1360.
122. Rani N, et al. Structure–activity relationship studies of substituted imidazole derivatives. *Eur J Med Chem*. 2018;146:585–600.
123. Gao Y, et al. Design and synthesis of imidazole derivatives with enhanced antifungal activity. *Bioorg Med Chem*. 2019;27:347–356.
124. Lipinski CA. Drug-like properties and the role of lipophilicity. *Drug Discov Today Technol*. 2004;1:337–341.
125. Di L, Kerns EH. Drug-like properties: concepts, structure design and methods. Elsevier; 2016.
126. Ortiz de Montellano PR. Cytochrome P450: structure, mechanism, and biochemistry. Springer; 2015.
127. Kelly SL, Kelly DE. Microbial cytochrome P450 and antifungal resistance. *Biochim Biophys Acta*. 2013;1834:125–131.
128. Zhang J, et al. Electronic effects of azole substituents on antifungal activity. *J Med Chem*. 2017;60:110–123.
129. Meanwell NA. Rational drug design and SAR-based optimization. *J Med Chem*. 2016;59:3883–3908.
130. Perfect JR. The antifungal pipeline: a reality check. *Nat Rev Drug Discov*. 2017;16:603–616.
131. Wiederhold NP. Antifungal resistance: current trends and future strategies. *Clin Infect Dis*. 2017;64:S522–S528.
132. Parks LW, Casey WM. Physiological implications of ergosterol biosynthesis in fungi. *Annu Rev Microbiol*. 1995;49:95–116.

133. Dupont S, et al. Ergosterol biosynthesis as a target for antifungal drugs. *Biochem Soc Trans*. 2012;40:1021–1026.
134. Vanden Bossche H, et al. Mechanism of action of azole antifungals. *Drug Dev Res*. 1987;11:223–235.
135. Kelly SL, et al. Azole resistance in fungi: molecular mechanisms. *Trends Microbiol*. 1997;5:221–226.
136. Warrilow AGS, et al. Lanosterol 14α-demethylase (CYP51) structure and inhibition. *J Biol Chem*. 2013;288:17781–17790.
137. Guengerich FP. Cytochrome P450 and chemical toxicology. *Chem Res Toxicol*. 2008;21:70–83.
138. van der Rest ME, et al. Membrane effects of sterol biosynthesis inhibition. *Microbiology*. 1995;141:2401–2412.
139. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. *Trends Microbiol*. 2003;11:272–279.
140. Cowen LE. Hsp90 orchestrates stress response pathways in fungi. *PLoS Pathog*. 2009;5:e1000471.
141. Shingu-Vazquez M, Traven A. Mitochondria and fungal pathogenesis. *Cell Microbiol*. 2011;13:137–146.
142. Perfect JR. Is there an emerging need for new antifungals? *Nat Rev Drug Discov*. 2017;16:603–616.
143. Mosmann T. Rapid colorimetric assay for cellular growth and survival. *J Immunol Methods*. 1983;65:55–63.
144. Lipinski CA. Drug-like properties and medicinal chemistry optimization. *Drug Discov Today*. 2001;6:357–364.
145. Di L, Kerns EH. Profiling drug-like properties in discovery research. *Nat Rev Drug Discov*. 2008;7:557–568.
146. Ekins S, et al. Computational approaches to drug ADMET. *J Pharmacol Toxicol Methods*. 2007;55:119–129.
147. Lewis RE. Current concepts in antifungal pharmacology. *Mayo Clin Proc*. 2011;86:805–817.
148. Wiederhold NP. Antifungal resistance and future strategies. *Clin Infect Dis*. 2017;64:S522–S528.
149. Roughley SD, Jordan AM. The medicinal chemist's toolbox: synthetic complexity and scalability. *J Med Chem*. 2011;54:3451–3479.
150. Sheldon RA. Green and sustainable manufacture of chemicals. *Green Chem*. 2014;16:950–963.
151. Andes DR, et al. In vivo pharmacodynamics of antifungal agents. *Antimicrob Agents Chemother*. 2004;48:3606–3613.
152. Lionakis MS, et al. Animal models in fungal infection research. *Cold Spring Harb Perspect Med*. 2018;8:a019141.
153. Cowen LE, et al. Mechanisms of antifungal drug resistance. *Cold Spring Harb Perspect Med*. 2015;5:a019752.
154. Perlin DS. Echinocandin resistance and antifungal drug development. *Clin Infect Dis*. 2015;61:S612–S617.
155. Lipinski CA. Lead- and drug-like properties in medicinal chemistry. *Drug Discov Today Technol*. 2004;1:337–341.
156. Keri RS, et al. Hybrid molecules in antifungal drug discovery. *Eur J Med Chem*. 2015;89:207–251.
157. Cherkasov A, et al. QSAR modeling in drug discovery. *J Med Chem*. 2014;57:4977–5010.
158. Schneider G. Automating drug discovery with AI. *Nat Rev Drug Discov*. 2018;17:97–113.
159. Perfect JR. Antifungal drug development: the road ahead. *Nat Rev Drug Discov*. 2017;16:603–616.